SELLAS Life Sciences (SLS) Accumulated Expenses (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Accumulated Expenses of $2.3 million for Q1 2026, down 12.06% year-over-year from $2.6 million in Q1 2025, and down 35.86% quarter-over-quarter from $3.5 million in Q4 2025.
SELLAS Life Sciences (SLS) Accumulated Expenses (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Accumulated Expenses for 17 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 12.06% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 12.06% YoY), while the FY2025 annual figure was $3.5 million, down 35.51% from the prior year.
- Accumulated Expenses declined to $2.3 million in Q1 2026 per SLS's latest filing, from $3.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $7.6 million in Q4 2023 and bottomed at $2.1 million in Q2 2025.
- Historically, Accumulated Expenses has averaged $4.7 million across 5 years, with a median of $5.2 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 138.11% — and 2025, when it slumped 60.7%.
- SELLAS Life Sciences' Accumulated Expenses stood at $6.3 million in 2022, then increased by 21.7% to $7.6 million in 2023, then dropped by 28.55% to $5.5 million in 2024, then plunged by 35.51% to $3.5 million in 2025, then slumped by 35.86% to $2.3 million in 2026.
- Business Quant data shows SLS's Accumulated Expenses at $2.3 million in Q1 2026, $3.5 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.90 Mn |
| Mar 31, 2026 | 2.26 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 3.02 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 5.47 Mn |
| Sep 30, 2024 | 5.49 Mn |
| Jun 30, 2024 | 5.18 Mn |
| Mar 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | 7.65 Mn |
| Sep 30, 2023 | 6.93 Mn |
| Jun 30, 2023 | 6.24 Mn |
| Mar 31, 2023 | 6.49 Mn |
| Dec 31, 2022 | 6.29 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 3.01 Mn |
| Mar 31, 2022 | 3.01 Mn |
| Dec 31, 2021 | 2.64 Mn |
| Sep 30, 2021 | 2.58 Mn |